1932

Abstract

“New Therapeutic Targets” is the theme of articles in the , Volume 59. Reviews in this volume discuss targets for a variety of conditions in need of new therapies, including type 2 diabetes, heart failure with preserved ejection fraction, obesity, thyroid-associated ophthalmopathy, tinnitus, multiple sclerosis, Parkinson's disease and other neurodegenerative diseases, pain, depression, post-traumatic stress disorder, muscle wasting diseases, cancer, and anemia associated with chronic renal disease. Numerous articles in this volume focus on the identification, validation, and utility of novel therapeutic targets, in particular, ones that involve new or unexpected molecular entities. This theme complements several previous themes, including “New Approaches for Studying Drug and Toxicant Action: Applications to Drug Discovery and Development,” “Precision Medicine and Prediction in Pharmacology,” and “New Methods and Novel Therapeutic Approaches in Pharmacology and Toxicology.”

Loading

Article metrics loading...

/content/journals/10.1146/annurev-pharmtox-101018-112717
2019-01-06
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/pharmtox/59/1/annurev-pharmtox-101018-112717.html?itemId=/content/journals/10.1146/annurev-pharmtox-101018-112717&mimeType=html&fmt=ahah

Literature Cited

  1. 1.  Perrino C, Barabási AL, Condorelli G, Davidson SM, De Windt L et al. 2018. Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc. Res. 113:725–36
    [Google Scholar]
  2. 2.  Benstead-Hume G, Wooller SK, Pearl FMG 2017. ‘Big data’ approaches for novel anti-cancer drug discovery. Expert. Opin. Drug Discov. 12:599–609
    [Google Scholar]
  3. 3.  Xie L, Draizen EJ, Bourne PE 2016. Harnessing big data for systems pharmacology. Annu. Rev. Pharmacol. Toxicol. 57:245–62
    [Google Scholar]
  4. 4.  van Hasselt JGC, Iyengar R 2019. Systems pharmacology: defining the interactions of drug combinations. Annu. Rev. Pharmacol. Toxicol. 59:21–40
    [Google Scholar]
  5. 5.  Buzdin A, Sorokin M, Garazha A, Sekacheva M, Kim E et al. 2018. Molecular pathway activation—new type of biomarkers for tumor morphology and personalized selection of target drugs. Semin. Cancer Biol. In press. https://doi.org/10.1016/j.semcancer.2018.06.003
    [Crossref]
  6. 6.  Rabbini M, Kanevsky J, Kali K, Chandelier F, Giles FJ 2018. Role of artificial intelligence in the care of patients with non-small cell lung cancer. Eur. J. Clin. Investig. 48:e12901
    [Google Scholar]
  7. 7.  Krittanawong C, Zhang H, Wang Z, Avdar M, Kitai T 2017. Artificial intelligence in precision cardiovascular medicine. J. Am. Coll. Cardiol. 69:2657–64
    [Google Scholar]
  8. 8.  Insel PA, Amara SG, Blaschke TF 2015. Introduction to the theme “Precision medicine and prediction in pharmacology. .” Annu. Rev. Pharmacol. Toxicol. 55:11–14
    [Google Scholar]
  9. 9.  Peck RW 2018. Precision medicine is not just genomics: the right dose for every patient. Annu. Rev. Pharmacol. Toxicol. 58:105–22
    [Google Scholar]
  10. 10.  Patel RB, Shah SJ 2019. Drug targets for heart failure with preserved ejection fraction: a mechanistic approach and review of contemporary clinical trials. Annu. Rev. Pharmacol. Toxicol. 59:41–63
    [Google Scholar]
  11. 11.  Goedeke L, Perry RJ, Shulman GI 2019. Emerging pharmacological targets for the treatment of nonalcoholic fatty liver disease, insulin resistance, and type 2 diabetes. Annu. Rev. Pharmacol. Toxicol. 59:65–87
    [Google Scholar]
  12. 12.  Heindel JJ, Blumberg B 2019. Environmental obesogens: mechanisms and controversies. Annu. Rev. Pharmacol. Toxicol. 59:89–106
    [Google Scholar]
  13. 13.  Niedzwiecki MM, Walker DI, Vermeulen R, Chadeau-Hyam M, Jones DP, Miller GW 2019. The exposome: molecules to populations. Annu. Rev. Pharmacol. Toxicol. 59:107–27
    [Google Scholar]
  14. 14.  Smith TJ 2019. Challenges in orphan drug development: identification of effective therapy for thyroid-associated ophthalmopathy. Annu. Rev. Pharmacol. Toxicol. 59:129–48
    [Google Scholar]
  15. 15.  Chun JJM, Kihara Y, Jonnalagadda D, Blaho VA 2019. Fingolimod: lessons learned and new opportunities for treating multiple sclerosis and other disorders. Annu. Rev. Pharmacol. Toxicol. 59:149–70
    [Google Scholar]
  16. 16.  Gould TD, Zarate CA Jr., Thompson SM 2019. Molecular pharmacology and neurobiology of rapid-acting antidepressants. Annu. Rev. Pharmacol. Toxicol. 59:213–36
    [Google Scholar]
  17. 17.  Abdallah CG, Averill LA, Akiki TJ, Raza M, Averill CL et al. 2019. The neurobiology and pharmacotherapy of posttraumatic stress disorder. Annu. Rev. Pharmacol. Toxicol. 59:171–89
    [Google Scholar]
  18. 18.  Benedetti F 2008. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu. Rev. Pharmacol. Toxicol. 48:33–60
    [Google Scholar]
  19. 19.  Benedetti F 2014. Placebo effects: from the neurobiological paradigm to translational implications. Neuron 84:623–37
    [Google Scholar]
  20. 20.  Colloca L 2019. The placebo effect in pain therapies. Annu. Rev. Pharmacol. Toxicol. 59:191–211
    [Google Scholar]
  21. 21.  Moutinho M, Codocedo JF, Puntambekar SS, Landreth GE2019 Nuclear receptors as therapeutic targets for neurodegenerative diseases: lost in translation. Annu. Rev. Pharmacol. Toxicol. 59:237–61
    [Google Scholar]
  22. 22.  Liss B, Striessnig J 2019. The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinson's disease. Annu. Rev. Pharmacol. Toxicol. 59:263–89
    [Google Scholar]
  23. 23.  Langguth B, Elgoyhen AB, Cederroth CR 2019. Therapeutic approaches to the treatment of tinnitus. Annu. Rev. Pharmacol. Toxicol. 59:291–313
    [Google Scholar]
  24. 24.  Furrer R, Handschin C 2019. Muscle wasting diseases: novel targets and treatments. Annu. Rev. Pharmacol. Toxicol. 59:315–39
    [Google Scholar]
  25. 25.  Eddleston M 2019. Novel clinical toxicology and pharmacology of organophosphorus insecticide self-poisoning. Annu. Rev. Pharmacol. Toxicol. 59:341–60
    [Google Scholar]
  26. 26.  Marshall HT, Djamgoz MBA 2018. Immuno-oncology: emerging targets and combination therapies. Front. Oncol. 8:315
    [Google Scholar]
  27. 27.  Kawakami M, Liu X, Dmitrovsky E 2019. New cell cycle inhibitors target aneuploidy in cancer therapy. Annu. Rev. Pharmacol. Toxicol. 59:361–77
    [Google Scholar]
  28. 28.  Semenza GL 2019. Pharmacologic targeting of hypoxia-inducible factors. Annu. Rev. Pharmacol. Toxicol. 59:379–403
    [Google Scholar]
  29. 29.  Parrish MC, Tan YJ, Grimes KV, Mochly-Rosen D 2019. Surviving in the valley of death: opportunities and challenges in translating academic drug discoveries. Annu. Rev. Pharmacol. Toxicol. 59:405–21
    [Google Scholar]
/content/journals/10.1146/annurev-pharmtox-101018-112717
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error